Meeting
2013 ASCO Annual Meeting
Uptake and disparities of neoadjuvant therapy for stage III non-small cell lung cancer.
Authors
Daniel Jacob Becker
St. Luke's Hospital, Roosevelt Hospital, Beth Israel Medical Center, Continuum Cancer Centers of New York, New York, NY
Daniel Jacob Becker , Benjamin Philip Levy , Michael L. Grossbard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research
Track
Health Services Research
Sub Track
Disparities/Health Equity
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6571)
DOI
10.1200/jco.2013.31.15_suppl.6571
Abstract #
6571
Poster Bd #
15C
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Palliative care usage in large cell lung carcinoma: An analysis of the National Cancer Database.
First Author: Emily Han
Poster
2023 ASCO Annual Meeting
SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—A multicenter phase II trial.
First Author: Laetitia A Mauti
Poster
2023 ASCO Annual Meeting
Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
First Author: Jiyun Lee
Poster
2023 ASCO Annual Meeting
Assessment of sociodemographic disparities in outcomes among pts with metastatic NSCLC (mNSCLC) receiving select immuno-oncology (IO) regimens: CORRELATE.
First Author: Stephen V. Liu